DRG Market Assessment reports

Primary, or essential, hypertension is defined as persistently elevated blood pressure (BP) without any identifiable cause. It is a major risk factor for various cardiovascular diseases (e.g.,…

Pulmonary arterial hypertension (PAH) is a rare and life-threatening disorder marked by considerable morbidity and mortality. A wide array of drugs are available for PAH management…

Pulmonary hypertension (PH) is a devastating disease, for which there is no cure. Despite the rarity of the disease, the potential commercial rewards from drugs approved for it are considerable,…

MARKET OUTLOOK Pulmonary arterial hypertension (PAH) is a rare and life-threatening disorder marked by considerable morbidity and mortality. Despite the availability of a wide array of drugs for…

Market Outlook Primary, or essential, hypertension is defined as persistently elevated blood pressure (BP) without any identifiable cause. It is a major risk factor for various cardiovascular…

Market Outlook Hyperaldosteronism is characterized by the excessive release of aldosterone hormone into the blood and the resulting rise in blood pressure. This disorder is a common cause of…

Hypertension is a chronic condition that can be effectively managed by a vast array of drugs, spanning many drug classes. The antihypertensive market is highly mature and most of its drug classes…

Hyperaldosteronism is a disorder that is characterized by the excessive release of aldosterone into the blood and is a common cause of secondary hypertension. The main goals of treatment are the…

Pulmonary hypertension (PH), particularly pulmonary arterial hypertension (PAH), is a rare but life-threatening disorder. Commercial interest in PH/PAH has increased recently due to significant…

Pulmonary hypertension (PH) is a devastating disease, for which there is no cure. Despite the rarity of the disease, the potential commercial rewards from drugs approved for it are considerable,…

Despite the recent launches of several new therapies, adding to the range of pharmacotherapies available for treating PAH, and contributing to the complexity of the PAH treatment algorithm, a…

Which Key Attributes Will Drive Physician Prescribing and Formulary Inclusion of Current and Emerging PAH Therapies? Pulmonary arterial hypertension (PAH) is a severe, progressive, debilitating…